IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 366 filers reported holding IONIS PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 1.27 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,668 | +44.0% | 36,801 | +31.2% | 0.00% | +33.3% |
| Q2 2023 | $1,158 | +17.8% | 28,043 | +2.3% | 0.00% | +50.0% |
| Q1 2023 | $983 | -1.0% | 27,422 | +4.9% | 0.00% | -33.3% |
| Q4 2022 | $993 | -99.9% | 26,140 | +52.6% | 0.00% | +50.0% |
| Q3 2022 | $757,000 | +205.2% | 17,135 | +155.0% | 0.00% | +100.0% |
| Q2 2022 | $248,000 | -4.6% | 6,720 | +1.7% | 0.00% | 0.0% |
| Q1 2022 | $260,000 | +21.5% | 6,605 | -6.2% | 0.00% | – |
| Q4 2021 | $214,000 | -8.5% | 7,043 | +1.7% | 0.00% | -100.0% |
| Q3 2021 | $234,000 | -82.3% | 6,922 | -79.1% | 0.00% | -66.7% |
| Q2 2021 | $1,323,000 | -48.5% | 33,166 | -42.3% | 0.00% | -50.0% |
| Q1 2021 | $2,568,000 | -24.8% | 57,476 | -5.0% | 0.01% | 0.0% |
| Q4 2020 | $3,415,000 | +38.1% | 60,513 | +16.2% | 0.01% | +20.0% |
| Q3 2020 | $2,473,000 | -15.7% | 52,097 | +4.2% | 0.01% | -28.6% |
| Q2 2020 | $2,935,000 | +86.0% | 49,984 | +50.8% | 0.01% | +75.0% |
| Q1 2020 | $1,578,000 | -20.1% | 33,144 | +0.5% | 0.00% | 0.0% |
| Q4 2019 | $1,975,000 | +1.9% | 32,964 | +9.3% | 0.00% | 0.0% |
| Q2 2019 | $1,938,000 | +35.2% | 30,172 | +70.3% | 0.00% | 0.0% |
| Q1 2019 | $1,433,000 | +80.0% | 17,713 | +16.1% | 0.00% | +100.0% |
| Q4 2018 | $796,000 | +12.3% | 15,263 | +11.2% | 0.00% | 0.0% |
| Q3 2018 | $709,000 | +24.0% | 13,728 | 0.0% | 0.00% | +100.0% |
| Q2 2018 | $572,000 | -14.2% | 13,728 | -9.1% | 0.00% | -50.0% |
| Q1 2018 | $667,000 | -12.0% | 15,103 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $758,000 | +8.6% | 15,103 | +13.6% | 0.00% | 0.0% |
| Q3 2017 | $698,000 | +12.6% | 13,296 | +9.0% | 0.00% | 0.0% |
| Q2 2017 | $620,000 | +26.8% | 12,200 | 0.0% | 0.00% | +100.0% |
| Q1 2017 | $489,000 | -16.6% | 12,200 | 0.0% | 0.00% | -50.0% |
| Q4 2016 | $586,000 | -42.8% | 12,200 | -56.4% | 0.00% | +100.0% |
| Q3 2016 | $1,024,000 | +40.1% | 28,000 | -10.9% | 0.00% | -50.0% |
| Q2 2016 | $731,000 | -42.5% | 31,425 | 0.0% | 0.00% | -60.0% |
| Q1 2016 | $1,271,000 | -15.7% | 31,425 | +29.1% | 0.01% | -16.7% |
| Q4 2015 | $1,507,000 | – | 24,335 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bellevue Group AG | 9,930,245 | $396,117,000 | 3.87% |
| Sicart Associates LLC | 368,409 | $14,696,000 | 3.50% |
| Camber Capital Management LP | 2,000,000 | $79,780,000 | 2.69% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 181,781 | $7,251,000 | 1.91% |
| SECTOR GAMMA AS | 263,488 | $10,511,000 | 1.86% |
| Parkman Healthcare Partners LLC | 136,380 | $5,440,000 | 1.19% |
| Eversept Partners, LP | 442,000 | $17,631,380 | 1.18% |
| Affinity Asset Advisors, LLC | 75,000 | $2,992,000 | 1.07% |
| TANAKA CAPITAL MANAGEMENT INC | 16,661 | $665,000 | 0.90% |
| Sonora Investment Management, LLC | 168,665 | $6,728,000 | 0.88% |